Never Miss a Potential Recovery Again

Sign up for Class
Action Alerts

Each year, class action lawsuits generate billions of dollars in settlement funds, but many shareholders fail to file a claim. Stay in the know regarding class action lawsuits by signing up for alerts.

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

$941,284,300 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

The market fluctuates, but we don’t. We give you straight answers from real attorneys who have spent decades helping shareholders protect their investments and recover their losses.

Settlements

$47.5 Million

QuantumScape Corporation

$24.6 Million

Loma Negra Industrial Argentina Sociedad Argentina

$14 Million

Corcept Therapeutics Incorporated

$9.5 Million

Babcock & Wilcox Enterprises, Inc.

$40 Million

U.S. Steel

$7 Million

Aqua Metals, Inc.

$7.025 Million

WideOpenWest, Inc.

$8.25 Million

Helios and Matheson Analytics Inc.

$13.85 Million

Illumina, Inc.

$14.5 Million

Avon Products Inc.

I think you’ve done a superb job and I really appreciate the way this case was handled.

The Honorable Ronald B. Rubin in Teoh v. Ferrantino, C.A. No. 356627 (Cir. Ct. for Montgomery Cnty., MD 2012)

…a model for how [the] great legal profession should conduct itself.

Justice Timothy S. Driscoll in Grossman v. State Bancorp, Inc., Index No. 600469/2011 (N.Y. Sup. Ct. Nassau Cnty. Nov. 29, 2011)

I find the firm to be well-qualified to serve as Lead Counsel.

The Honorable Andrew L. Carter, Jr. In Snyder v. Baozun Inc., No. 1:19-CV-11290 (S.D.N.Y. Sept. 8, 2020)

In appointing the Firm Lead Counsel, the Honorable Analisa Torres noted our “extensive experience” in securities litigation.

White Pine Invs. v. CVR Ref., LP, No. 20 CIV. 2863 (S.D.N.Y. Jan. 5, 2021)

Class Counsel have demonstrated that they are skilled in this area of the law and therefore adequate to represent the Settlement Class as well.

Furthermore, with the increasing importance of compliance and risk management, kyc for law firms has become an essential component of legal services.

The Honorable Barry Ted Moskowitz in In re Regulus Therapeutics Inc. Sec. Litig., No. 3:17-CV-182-BTM-RBB (S.D. Cal. Oct. 30, 2020)

Who We Are

1
1
1
1
1
1

We're here for you

Find an Attorney

Required Field

Coin Image

Don't hesitate

Find a Case

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

3

Days Left

PCRX

Pacira BioSciences, Inc.

Deadline

March 14 2025

Class Period

8/2/23 - 8/8/24

Allegations

According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court “found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid,” and, thus, eVenus is not infringing on anything. Pacira’s ‘495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the ‘495 patent calls into question the validity of the Company’s other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira’s common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day.

Class Period

8/2/23 - 8/8/24

Deadline

March 14 2025

Learn More

7

Days Left

XYZ

Block, Inc.

Deadline

March 18 2025

Class Period

2/26/20 - 4/30/24

Allegations

(a) Block had engaged in widespread and years-long compliance lapses at Square and Cash App, including by failing to conduct basic due diligence regarding its customers’ identities or the nature of customer transactions so as to prevent the platforms from being used for illegal or illicit activities; (b) Block had effectively created a haven for widespread illegal and illicit activities on its Square and Cash App platforms by imposing minimal obligations on customers seeking to open accounts, transact, and deposit or withdraw funds; encouraging the use of bitcoin; and pressuring the Company’s banking partners to forgo ordinary know your customer due diligence activities; (c) thousands of transactions on Square and Cash App were made in connection with a wide variety of illegal and illicit activities, including, inter alia, money laundering, child sexual abuse, sex trafficking, drug trafficking, terrorism financing, contract killings, and illicit payments to entities and persons subject to economic sanctions; (d) Block allowed its customers to withdraw funds even after the accounts had been flagged for potentially illegal or illicit activities; (e) Block customers could open up multiple accounts using fake identities in order to engage in illegal or illicit activities; (e) Block customers could open up multiple accounts using fake identities in order to engage in illegal or illicit activities; (f) Block’s senior leadership and the Board had failed to correct identified compliance deficiencies despite numerous red flags, internal employee reports of deficiencies, and customer complaints; (g) Block’s Cash App user metrics had been artificially inflated through the use of fake accounts and the ability of criminals and other bad actors to open multiple accounts; and (h), as a result of (a)-(g) above, Block was subject to a material, undisclosed risk of its conduct being exposed, thereby exposing the Company to reputational harm, adverse regulatory actions, the loss of business activity, and adverse impacts to the Company’s operations and financial results.

Class Period

2/26/20 - 4/30/24

Deadline

March 18 2025

Learn More

7

Days Left

IIPR

Innovative Industrial Properties, Inc.

Deadline

March 18 2025

Class Period

2/27/24 - 12/19/24

Allegations

(i) IIPR was experiencing significant declines in rent and property-management fees in connection with certain customer leases; (ii) the foregoing would likely impair the Company’s ability to maintain funds from operations and revenue growth; (iii) accordingly, IIPR’s leasing operations were less profitable than the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/27/24 - 12/19/24

Deadline

March 18 2025

Learn More

7

Days Left

FTAI

FTAI Aviation Ltd.

Deadline

March 18 2025

Class Period

7/23/24 - 1/15/25

Allegations

(1) the Company reported one-time engine sales as maintenance repair & overhaul revenue when FTAI only performs limited repair and maintenance work on the engine assets sold; (2) FTAI presents whole engine sales as individual module sales, thereby overstating sales and demand; (3) the Company depreciates engines that are not on lease, which misleadingly lowers the reported cost of goods sold and inflates EBITDA; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

7/23/24 - 1/15/25

Deadline

March 18 2025

Learn More

13

Days Left

CROX

Crocs, Inc.

Deadline

March 24 2025

Class Period

11/3/22 - 10/28/24

Allegations

(1) the nature and sustainability of footwear brand, HEYDUDE’s revenue growth by concealing that 2022 revenue growth was driven, in large part, by the Company’s efforts to stock third-party wholesalers and retailers following the February 2022 acquisition of HEYDUDE; (2) as the Company’s retail partners began to destock this excess inventory, waning product demand further negatively impacted the Company’s financial results; and (3) as a result, defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 10/28/24

Deadline

March 24 2025

Learn More

14

Days Left

CDLX

Cardlytics, Inc.

Deadline

March 25 2025

Class Period

3/14/24 - 8/7/24

Allegations

(1) increasing consumer engagement led to an increase in consumer incentives; (2) the Company could not increase its billings commensurate with the increased consumer engagement; (3) as a result, there was a significant risk that its revenue growth would slow or decline; (4) the changes to Ads Decision Engine, which led to increased consumer engagement, led to the “under-delivery” of budgets and customers billing estimates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/14/24 - 8/7/24

Deadline

March 25 2025

Learn More

14

Days Left

EPIX

ESSA Pharma Inc.

Deadline

March 25 2025

Class Period

12/12/23 - 10/31/24

Allegations

(i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten’s clinical, regulatory, and commercial prospects; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

12/12/23 - 10/31/24

Deadline

March 25 2025

Learn More

14

Days Left

NVO

Novo Nordisk A/S

Deadline

March 25 2025

Class Period

11/2/22 - 12/19/24

Allegations

According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, “a 68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. Following this news, Novo’s stock price fell by $18.44 per share to close at $85.00 per share.

Class Period

11/2/22 - 12/19/24

Deadline

March 25 2025

Learn More

20

Days Left

IAS

Integral Ad Science Holding Corp.

Deadline

March 31 2025

Class Period

3/2/23 - 2/27/24

Allegations

(i) IAS was experiencing a new material trend of increased competitive pricing pressures and as a result, IAS had been forced to cut prices to compensate for weakening demand and slowing revenue growth; (ii) IAS’s pricing function was no longer “favorable” and IAS could not sustain its pricing and drive price increases; (iii) pricing had become a key differentiator between IAS and its competitor necessary to close major renewals and new deals; (iv) the risks that competition “could result in increased pricing pressure” or “could put pressure on us to change our prices” had in fact transpired; and (v) as a result, the IAS’s public statements were materially false and misleading at all relevant times.

Class Period

3/2/23 - 2/27/24

Deadline

March 31 2025

Learn More

20

Days Left

GO

Grocery Outlet Holding Corp.

Deadline

March 31 2025

Class Period

11/7/23 - 5/7/24

Allegations

According to the complaint, after-market on May 7, 2024, Grocery Outlet announced its financial results for the first quarter of fiscal 2024, published significantly below-expectation guidance for the second quarter, and further reduced its guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on “unforeseen systems transition costs that surfaced at the end of the quarter” and the resulting “residual expense from our commission support program as we finish store physical inventory counts in the second quarter.” Following this news, Grocery Outlet’s stock price fell to $20.88 per share on May 8, 2024, a decline of about 19.38% in the span of just a single day.

Class Period

11/7/23 - 5/7/24

Deadline

March 31 2025

Learn More

20

Days Left

MODV

ModivCare Inc.

Deadline

March 31 2025

Class Period

11/3/22 - 9/15/24

Allegations

According to the filed complaint, defendants made false statements and/or concealed that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (2) the Company had insufficient liquidity; and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/3/22 - 9/15/24

Deadline

March 31 2025

Learn More

20

Days Left

TIXT

TELUS International (Cda) Inc.

Deadline

March 31 2025

Class Period

2/16/23 - 8/1/24

Allegations

(1) the Company’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) Telus International’s declining profitability was tied to the Company’s drive to develop AI capabilities; (3) Telus International’s shift toward AI put greater pressure on the Company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/16/23 - 8/1/24

Deadline

March 31 2025

Learn More

20

Days Left

WBA

Walgreens Boots Alliance, Inc.

Deadline

March 31 2025

Class Period

4/2/20 - 1/16/25

Allegations

(i) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; (ii) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm; (iii) Walgreens’ revenues from the sale of prescription medications were unsustainable to the extent that they derived from unlawful conduct; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

4/2/20 - 1/16/25

Deadline

March 31 2025

Learn More

20

Days Left

ARNC

Arconic Corporation

Deadline

March 31 2025

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Allegations

According to the filed complaint, defendants made false and/or misleading statements and/or failed to disclose that defendants stated in Arconic’s quarterly and annual reports issued during the Class Period that Arconic’s share repurchase programs were “intended to comply with Rule 10b5-1,” which prohibits securities trading on the basis of material nonpublic information, and that all of Arconic’s share purchases “were made in compliance with Rule 10b-18,” which provides a safe harbor for share repurchases that meet certain criteria, but does not provide a safe harbor for insider trading or other violations of the federal securities laws. However, at the time those statements were made, Arconic had made share repurchases while in possession of material nonpublic information, and therefore Arconic’s share repurchase programs were not in compliance with Rule 10b5-1, and the share repurchases were not made in compliance with Rule 10b-18. Further, defendants stated that they were continuing with share repurchases. Inasmuch as the Company was restrained by law from buying back stock during active negotiations with Apollo, the defendants’ statements with respect to ongoing stock repurchases signaled to the market that there were no, and had been no, ongoing negotiations. Accordingly, when speaking about the stock repurchases, the defendants were obligated to disclose the whole truth – that they were in, or had been in, negotiations with Apollo.

Class Period

This lawsuit is on behalf of a Class of all persons who sold publicly traded shares of Arconic common stock between April 19, 2022 and May 3, 2023, both dates inclusive.

Deadline

March 31 2025

Learn More

21

Days Left

NEM

Newmont Corporation

Deadline

April 1 2025

Class Period

2/22/24 - 10/23/24

Allegations

According to the complaint, on October 23, 2024, Newmont published a press release announcing disappointing EBITDA third quarter 2024 highlights, in addition to decreases in production and increases in operating costs. In pertinent part, Newmont revealed that mining operations at its two Tier 1 assets would see lower production than originally guided with expectations of higher costs at these facilities. Following this news, Newmont’s stock price fell from a closing market price of $57.74 per share on October 23, 2024 to $49.25 per share on October 24, 2024.

Class Period

2/22/24 - 10/23/24

Deadline

April 1 2025

Learn More

27

Days Left

NMRA

Neumora Therapeutics, Inc.

Deadline

April 7 2025

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Allegations

(1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora’s flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Class Period

This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023.

Deadline

April 7 2025

Learn More

27

Days Left

MPWR

Monolithic Power Systems Inc.

Deadline

April 7 2025

Class Period

2/8/24 - 11/8/24

Allegations

(a) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (b) the defects listed in (a), above, had, in turn, negatively impacted the performance of certain products offered by the Company's largest customer, Nvidia, in which such products were used; (c) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions the Company supplied to Nvidia; (d) Monolithic’s relationship with Nvidia had been irreparably damaged due to the significant performance and quality control.

Class Period

2/8/24 - 11/8/24

Deadline

April 7 2025

Learn More

27

Days Left

GSK

GSK plc

Deadline

April 7 2025

Class Period

2/5/20 - 8/14/22

Allegations

According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators.” GSK also stated that it was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability.” These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.

Class Period

2/5/20 - 8/14/22

Deadline

April 7 2025

Learn More

31

Days Left

ICLR

ICON Public Limited Company

Deadline

April 11 2025

Class Period

7/27/23 - 10/23/24

Allegations

(a)ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company’s client base; (b)ICON’s purported functional service provision and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d)ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e)ICON’s two largest customers were diversifying their clinical research organization providers away from the Company; (f)as a result of (a)-(e) above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (g)as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the Class Period and such guidance lacked a reasonable factual basis.

Class Period

7/27/23 - 10/23/24

Deadline

April 11 2025

Learn More

34

Days Left

ESTC

Elastic N.V.

Deadline

April 14 2025

Class Period

5/31/24 - 8/29/24

Allegations

(i) Elastic had implemented significant changes to its sales operations, particularly with respect to its customer segments in the Americas; (ii) the foregoing changes were likely to, and did, disrupt Elastic’s sales operations during the first quarter of its FY 2025; (iii) accordingly, defendants had overstated the stability of Elastic’s sales operations; (iv) as a result of all the foregoing, Elastic was unlikely to meet its own previously issued revenue guidance for its FY 2025; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

5/31/24 - 8/29/24

Deadline

April 14 2025

Learn More

34

Days Left

NTLA

Intellia Therapeutics, Inc.

Deadline

April 14 2025

Class Period

7/30/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia’s resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company’s once-touted NTLA-3001’s discontinuation. Following this news, Intellia’s stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025.

Class Period

7/30/24 - 1/8/25

Deadline

April 14 2025

Learn More

34

Days Left

EIX

Edison International

Deadline

April 14 2025

Class Period

2/25/21 - 2/6/25

Allegations

(1) Edison’s claim that southern California Edison company used its public safety power shutoffs program to “proactively de-energize power lines to mitigate the risk of catastrophic wildfires during extreme weather events”, was false; (2) this resulted in heightened fire risk in California and heightened legal exposure to the Company; and (3) as a result, defendants’ statements about Edison’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Class Period

2/25/21 - 2/6/25

Deadline

April 14 2025

Learn More

34

Days Left

MRK

Merck & Co., Inc.

Deadline

April 14 2025

Class Period

2/3/22 - 2/3/25

Allegations

According to the complaint, defendants provided investors with material information concerning Merck’s expected revenue of $11 billion from sales of Gardasil by 2030. Defendants’ statements included, among other things, confidence in Merck’s purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil’s growth in China. The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.” Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had “not recovered to the level we had expected.” Following this news, Merck’s common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck’s stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

Class Period

2/3/22 - 2/3/25

Deadline

April 14 2025

Learn More

34

Days Left

FMC

FMC Corporation

Deadline

April 14 2025

Class Period

11/16/23 - 2/4/25

Allegations

(1) the Company’s channel management initiatives were not progressing as represented; (2) faced with pricing pressure, the Company had made the decision not to compete on prices and instead walk away from sales opportunities; (3) the Company had inflated inventory in the channels in “Latin America, including Brazil, Asia, including India, as well as Canada and Eastern Europe;” and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/16/23 - 2/4/25

Deadline

April 14 2025

Learn More

35

Days Left

TMDX

TransMedics Group, Inc.

Deadline

April 15 2025

Class Period

2/28/23 - 1/10/25

Allegations

(1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices and hid safety issues and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/28/23 - 1/10/25

Deadline

April 15 2025

Learn More

35

Days Left

ALAR

Alarum Technologies Ltd.

Deadline

April 15 2025

Class Period

3/14/24 - 8/26/24

Allegations

(i) the Company was less effective in retaining and/or expanding customer engagements than it had represented to investors; (ii) the foregoing would impair Alarum’s ability to generate consistent revenue growth; (iii) accordingly, Alarum’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/14/24 - 8/26/24

Deadline

April 15 2025

Learn More

38

Days Left

VG

Venture Global, Inc.

Deadline

April 18 2025

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Allegations

According to the complaint, Venture completed its initial public offering on January 27, 2025, selling 70 million shares at $24.00 per share. On February 5, 2025, TotalEnergies, an energy company that was a target customer of Venture, rejected opportunities to become a long-term customer of Venture, citing lack of trust. In particular, TotalEnergies CEO, stated that he was approached by Venture to see if the company would be interested in a long-term supply contract for liquefied natural gas from the Calcasieu Pass terminal in Louisiana, but he rejected the offer “because of what they are doing.” Venture is currently facing legal challenges from existing large clients, such as BP and Shell, due to delays in supply contracts as Venture commissions its projects. Given the fact that defendants ability to deliver liquefied natural gas (LNG) to the world and to continue development of Venture’s five natural gas liquefication and export projects depends on customer contracts, defendants’ failure to account for and address these issues caused statements in Venture’s registration statement to be false and/or materially misleading at the time of the initial public offering.

Class Period

This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to Venture’s registration statement for the initial public offering held on or about January 24, 2025.

Deadline

April 18 2025

Learn More

41

Days Left

STZ

Constellation Brands, Inc.

Deadline

April 21 2025

Class Period

4/11/24 - 1/8/25

Allegations

According to the complaint, defendants provided investors with material information concerning Constellation’s full year 2024 fiscal results and financial outlook for 2025 which was based in material part on defendants enhanced focus on improving mix, inventory and sales execution in its Wine and Spirits business, specifically focusing efforts within its premium and above brands to drive more consistent growth. Additionally, defendants made investments in media spend and price promotions as well as adjustments in sales capabilities to support distributor partners. On January 8, 2025 defendants issued a press release announcing the Company’s third quarter fiscal year 2025 results. In pertinent part, defendants presented a significant miss on sales performance in the Beer segment and an even steeper miss for the Wine & Spirits. Following this news, the price of Constellation’s common stock declined dramatically. From a closing market price of $219.28 per share on January 8, 2025 to $181.81 per share on January 10, 2025.

Class Period

4/11/24 - 1/8/25

Deadline

April 21 2025

Learn More

41

Days Left

TTD

The Trade Desk, Inc.

Deadline

April 21 2025

Class Period

5/9/24 - 2/12/25

Allegations

(1) Trade Desk was experiencing significant, ongoing, self-inflicted execution challenges rolling out the Company's AI forecasting tool, Kokai, including transitioning clients to Kokai from the Company’s older platform Solimar; (2) such execution challenges meaningfully delayed the Kokai Rollout; (3) Trade Desk’s inability to effectively execute the Kokai Rollout negatively impacted the Company’s business and operations, particularly revenue growth; and (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

5/9/24 - 2/12/25

Deadline

April 21 2025

Learn More

42

Days Left

SMTC

Semtech Corporation

Deadline

April 22 2025

Class Period

8/27/24 - 2/7/25

Allegations

(1) its CopperEdge products did not meet the needs of its server rack customer or end users; (2) as a result, the CopperEdge products required certain rack architecture changes; (3) as a result of the foregoing, the Company’s sales of CopperEdge products would not ramp-up during fiscal 2026; (4) as a result, sales of CopperEdge products would be lower-than-expected; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/27/24 - 2/7/25

Deadline

April 22 2025

Learn More

43

Days Left

ATKR

Atkore Inc.

Deadline

April 23 2025

Class Period

2/1/24 - 2/3/25

Allegations

(1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, the Company and its price-fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result, defendants’ positive statements Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Class Period

2/1/24 - 2/3/25

Deadline

April 23 2025

Learn More

48

Days Left

QUBT

Quantum Computing Inc.

Deadline

April 28 2025

Class Period

3/30/20 - 1/15/25

Allegations

(i) defendants overstated the capabilities of QCI’s quantum computing technologies, products, and/or services; (ii) defendants overstated the scope and nature of QCI’s relationship with NASA, as well as the scope and nature of QCI’s NASA-related contracts and/or subcontracts; (iii) defendants overstated QCI’s progress in developing a thin film lithium niobate, TFLN foundry, the scale of the purported TFLN foundry, and orders for the Company’s TFLN chips; (iv) QCI’s business dealings with Quad M and millionways both qualified as related party transactions; (v) accordingly, QCI’s revenues relied, at least in part, on undisclosed related party transactions; (vi) all the foregoing, once revealed, was likely to have a significant negative impact on QCI’s business and reputation; and (vii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

3/30/20 - 1/15/25

Deadline

April 28 2025

Learn More

48

Days Left

MANH

Manhattan Associates, Inc.

Deadline

April 28 2025

Class Period

10/22/24 - 1/28/25

Allegations

According to the complaint, defendants provided investors with material information concerning Manhattan Associates’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s ability to forecast guidance despite macroeconomic fluctuations, the growth potential of their professional services offerings, and the ability for their cloud revenue to drive revenue for its professional services. On January 28, 2025, Manhattan Associates published its financial results for the fourth quarter and full fiscal year 2024 and announced reduced revenue guidance for the full fiscal year 2025. The Company attributed its results and lowered guidance on the “shift in professional services work to future periods . . . and to a lesser extent, reduced customization and higher partner utilization.” Following this news, the price of Manhattan Associates’ common stock declined dramatically from a closing market price of $295.10 per share on January 28, 2025, to $222.84 per share on January 29, 2025, a decline of about 24.49% in the span of just a single day.

Class Period

10/22/24 - 1/28/25

Deadline

April 28 2025

Learn More

48

Days Left

RKLB

Rocket Lab USA, Inc.

Deadline

April 28 2025

Class Period

11/12/24 - 2/25/25

Allegations

(1) the Company’s plans for three barge landing tests were significantly delayed; (2) a critical potable water problem was not scheduled to be fixed until January 2026, which delayed preparation of the launch pad; (3) as a result of the foregoing, there was a substantial risk that Rocket Lab’s Neutron rocket would not launch in mid-2025; (4) Neutron’s only contract was made at a discount with an unreliable partner; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/12/24 - 2/25/25

Deadline

April 28 2025

Learn More

55

Days Left

ELF

e.l.f. Beauty, Inc.

Deadline

May 5 2025

Class Period

11/1/23 - 11/19/24

Allegations

(i) contrary to its representations to investors, the Company was experiencing rising inventory levels as a consequence of flagging sales; (ii) Elf falsely attributed the rising inventory levels to, among other things, changes in its sourcing practices; (iii) to maintain investor confidence, Elf reported inflated revenue, profits, and inventory over several quarters; (iv) the Company’s business and/or financial prospects were overstated; (v) all of the foregoing, once revealed, would likely have a material negative impact on the Company; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

11/1/23 - 11/19/24

Deadline

May 5 2025

Learn More

55

Days Left

SWKS

Skyworks Solutions, Inc.

Deadline

May 5 2025

Class Period

7/30/24 - 2/5/25

Allegations

According to the complaint, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings. On February 5, 2025, after market close, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025. The Company attributed its results and low guidance to a “competitive landscape” that had “intensified” in recent years. Following this news, the price of Skyworks’ common stock declined dramatically. From a closing market price of $87.08 per share on February 5, 2025, Skyworks’ stock price fell to $65.60 per share on February 6, 2025, a decline of over 24% in the span of just a single day.

Class Period

7/30/24 - 2/5/25

Deadline

May 5 2025

Learn More

55

Days Left

APP

AppLovin Corporation

Deadline

May 5 2025

Class Period

5/10/23 - 2/25/25

Allegations

According to the complaint, defendants provided investors with material information concerning AppLovin’s financial growth and stability. Defendants’ statements included, among other things, confidence in AppLovin’s launch of its AXON 2.0 digital ad platform and using “cutting-edge AI technologies” to more efficiently match advertisements to mobile games, in addition to expanding into web-based marketing and e-commerce. Moreover, defendants publicly reported impressive financial results, outlooks, and guidance to investors, all while using dishonest advertising practices. The truth emerged on February 26, 2025, when analyst research reports emerged stating that AppLovin was reverse engineering and exploiting advertising data from Meta Platforms. The reports further alleged AppLovin was utilizing manipulative practices to artificially inflate their own ad click-through and app download rates, such as by having ads click on themselves or utilizing design gimmicks to trigger forced shadow downloads, erroneously inflating installation numbers and, in turn, its profit figures. Following this news, the price of AppLovin’s stock declined from $377.06 per share on February 25, 2025 to $331.00 per share on February 26, 2025.

Class Period

5/10/23 - 2/25/25

Deadline

May 5 2025

Learn More

55

Days Left

MRVI

Maravai LifeSciences Holdings, Inc.

Deadline

May 5 2025

Class Period

8/7/24 - 2/24/25

Allegations

(1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

8/7/24 - 2/24/25

Deadline

May 5 2025

Learn More

55

Days Left

RC

Ready Capital Corporation

Deadline

May 5 2025

Class Period

11/7/24 - 3/2/25

Allegations

(1) significant non-performing loans in its CRE portfolio were not likely to be collectible; (2) Ready Capital would fully reserve these problem loans in order to “stabilize” its CRE portfolio; (3) this was not accurately reflected in Ready Capital’s current expected credit loss or valuation allowances; (4) as a result, the Company’s financial results would be adversely affected; and (5), as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

11/7/24 - 3/2/25

Deadline

May 5 2025

Learn More

View All Deadlines

News

Stay informed with the latest in settlement notices, case updates, publications, analyst reports, and more.
View All News

Learn More

ARNC Botches Buyout -- Investors Sue
Arconic investors are enraged after the company’s executives seriously botched a buyout offer, costing investors a lot of cash.  Furious investors have filed a class-action against Arconic to recover some of their losses from the botched deal.    In 2022, Arconic received a buy-out offer from Apollo.  Apollo offered to buy every Arconic share for $7...Read more

March 10, 2025

Learn More

FMC Revenue Down 5% -- Investors Take Legal Action
Pesticides manufacturer FMC killed investors’ hopes when it missed its revenue guidance because of sales downturn. Furious investors plucked their shares out of FMC, causing the Company’s stock price to fall 33% overnight. Some investors have filed a class-action against FMC to recover their lost “green.” In late 2023, FMC announced its annual outlook, projecting...Read more

March 7, 2025

Learn More

Levi & Korsinsky to Represent iLearning Engines Investors
Walker v. iLearningsEnginges, Inc., 8-24-cv-02900 is a case currently pending before Judge Deborah K. Chasanow of the U.S. District Court for the District of Maryland.  Plaintiffs in the case allege iLearning reported fraudulent revenue and expenses due to undisclosed and faked related-party transactions.   On February 27, 2025, Judge Chasanow appointed Louis Leveque as lead plaintiff...Read more

March 5, 2025

View All News

Our World-Class Team

Levi & Korsinsky’s attorneys are admitted in over 40 state, federal, and appeal courts across the country. We have the specialized securities skills to achieve outstanding results, and our impressive variety of backgrounds means that we can go up against large companies of any kind and win. Our powerhouse attorneys have backgrounds in accounting, engineering, SEC enforcement, mathematics, regulatory analysis, international business, and prosecution, to name just a few. . .

View Attorneys